Segmented and total direct cost-of-care for advanced squamous cell carcinoma of the head and neck in a privately insured population
Introduction: Current treatment recommendations for advanced SCCHN include the use of combined modality therapy (e.g., radiation plus chemotherapy/biologic therapy). The new biologic agent, cetuximab, is considered a primary cost driver for SCCHN management. Cetuximab’s impact, however, has not be...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | en_US |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/2152/22221 |